GUERBET (EPA:GBT) Guerbet - 2011 third-quarter sales
Transparency directive : regulatory news
25/10/2011 19:03
Click here to download pdf version
PRESS RELEASE
2011 third-quarter revenue
Villepinte, 26 October 2011
Consolidated Group revenue (IFRS)
In thousands of euros 2011 2010 Change
First quarter.............. 95,053 86,684 +9.7%
Second quarter............. 98,559 92,220 +6.9%
Third quarter.............. 87,138 82,797 +5.2%
Total....................280,750 261,701 +7.3%
Consolidated revenue by region
In thousands of euros 2011 2010 Change
European subsidiaries....... 198,215 190,610 +4.0%
Other markets............... 82,535 71,090 +16.1%
Total....................... 280,750 261,701 +7.3%
2011 third-quarter sales highlights and full-year outlook
In the third quarter, Dotarem registered continued growth (+12.6% in value) with
consistent performances across Europe and further gains in other markets. Over
the same period, Xenetix experienced an acceleration with sales growth of 7.7%,
particularly from momentum outside of Europe (+12.6%).
Year-to-date for the nine-month period ended 30 September, sales grew 7.3%
driven by Dotarem (+15.3%), Lipiodol (+55.0%) and Xenetix (+3.7%). Asia, Latin
America and North America accounted for 60% of total growth.
Since the beginning of the year, no production incidents were experienced
adversely affecting activity. For year end, the trend of the first nine months
is expected to be confirmed.
Contact: Administrative and Finance Department - Tel.: 01 45 91 50 69